Results 231 to 240 of about 68,288 (264)

A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription. [PDF]

Nat Commun
Minello A, Gomez-Escudero J, Sridhara SC, Martin C, Girard E, Cañas JC, Memari Y, Bustos MR, Galarreta A, Boucherit V, Imyanitov E, Bodvarsdottir SK, Baulande S, Vincent-Salomon A, Servant N, Altmeyer M, Sigurdsson S, Stoppa-Lyonnet D, Nik-Zainal S, Carreira A.   +19 more
europepmc   +1 more source

Germline <i>BRCA</i> testing in routine clinical practice: a single-center experience. [PDF]

Pathol Oncol Res
Nikolényi A, Dobi Á, Sántha D, Kószó R, Iványi M, Horváth E, Enyedi MZ, Priskin K, Csányi B, Patócs A, Butz H, Papp J, Varga Z, Tóth R, Oláh J, Kahán Z.   +15 more
europepmc   +1 more source

Functional analysis of BRCA1 and BRCA2 splicing variants using a minigene assay. [PDF]

Hum Genomics
Yim H, Youn S, Chae SW, Kim Y, Jang J, Cho SI, Lee JS, Seong MW.   +7 more
europepmc   +1 more source

CldU sensitizes <i>BRCA2</i> reverse-mutated cells to PARP inhibitors. [PDF]

Front Oncol
Zouggari N, Trugenberger C, Du Bois V, Wang W, Rossetti GG, Halazonetis TD, Labidi-Galy I.   +6 more
europepmc   +1 more source

Case Report: Individualized circulating tumor DNA monitoring guides olaparib adjuvant therapy: an early-stage breast cancer case with somatic BRCA2 mutation. [PDF]

Front Oncol
You Q, Gong L, Chen Y, Dinglin X, Cheng Z, Xia Q, Xie J, Zhao J, Su F.   +8 more
europepmc   +1 more source

Characteristics of Germline and Somatic Mutations of DNA Repair Genes in Korean Men with Prostate Cancer. [PDF]

World J Mens Health
Lee H, Ho JN, Song SH, Oh JJ, Huh JS, Kim HM, Kim KH, Kim S, Byun SS.   +8 more
europepmc   +1 more source

Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of <i>BRCA1</i> or <i>BRCA2</i> Pathogenic Variants. [PDF]

World J Oncol
Abdel-Razeq H, Mansour R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2

Journal of Clinical Oncology, 2021
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogenic variant (PV). This investigator-initiated, single-arm
K. Reiss, R. Mick, M. O'Hara, U. Teitelbaum, T. Karasic, C. Schneider, Stacy Cowden, T. Southwell, Janae Romeo, Natallia Izgur, Zain M Hannan, R. Tondon, K. Nathanson, R. Vonderheide, Max M. Wattenberg, G. Beatty, S. Domchek   +16 more
semanticscholar   +1 more source